CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr 28, 2020–
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data from across its portfolio will be presented at the ASGCT annual meeting, to be held May 12-15, 2020.
“Magenta’s pipeline continues to deliver new results and continues our progress toward our goal of allowing all patients who can benefit to receive curative stem cell gene therapy or transplant. Our ASGCT presentations demonstrate the far-reaching potential of our programs to widen availability of and improve the patient experience with stem cell gene therapy and transplant,” said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta Therapeutics. “We are particularly encouraged by the new results on our first-line mobilization and conditioning medicines for patients.”
Data from MGTA-145 First-Line